BIOMAT Database Logo BIOMAT Database Logo

Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori. 1993

T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000658 Amoxicillin A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration. Hydroxyampicillin,Actimoxi,Amoxicillin Anhydrous,Amoxicillin Monopotassium Salt,Amoxicillin Monosodium Salt,Amoxicillin Sodium,Amoxicillin Trihydrate,Amoxicillin, (R*)-Isomer,Amoxicilline,Amoxil,Amoxycillin,BRL-2333,Clamoxyl,Clamoxyl G.A.,Clamoxyl Parenteral,Penamox,Polymox,Trimox,Wymox,BRL 2333,BRL2333
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D013276 Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastric Ulcer,Gastric Ulcers,Stomach Ulcers,Ulcer, Gastric,Ulcer, Stomach,Ulcers, Gastric,Ulcers, Stomach
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae
D016481 Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. Infections, Helicobacter,Helicobacter Infection,Infection, Helicobacter

Related Publications

T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
January 1995, Journal of clinical gastroenterology,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
January 1992, Scandinavian journal of gastroenterology,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Helicobacter pylori infection and long term proton pump inhibitor therapy.
January 2004, Gut,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis.
January 2006, Gut,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori.
April 2002, Alimentary pharmacology & therapeutics,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
August 1995, Biological & pharmaceutical bulletin,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.
January 2020, Alimentary pharmacology & therapeutics,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Proton pump inhibitor therapy and Helicobacter pylori infection: a complicated relationship.
September 2006, Basic & clinical pharmacology & toxicology,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer.
June 2018, BMJ evidence-based medicine,
T Arakawa, and S Kimura, and T Uchida, and K Higuchi, and T Fukuda, and K Kobayashi
Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy.
September 2012, Journal of clinical biochemistry and nutrition,
Copied contents to your clipboard!